Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Martinsried - San Diego, May 4, 2004. Eligard®, the first drug of the German-American biotechnology company MediGene AG (Frankfurt, Prime Standard: MDG), is available in German pharmacies today. With the launch of the prescription drug to treat ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Martinsried - San Diego, March 31, 2004. The German-American biotech company MediGene AG (Frankfurt, Prime Standard: MDG) has achieved excellent results in a European phase 3 trial of the ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Martinsried - San Diego, March 24, 2004. After successful closure of the first step of the three-step capital increase measures announced on March 4, 2004, the German-American biotech company ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Martinsried - San Diego, March 4, 2004. The German-American biotech company MediGene AG (Frankfurt, Prime Standard: MDG) has finalized a three-step corporate action to increase cash available by approx. 16 million EUR. The first step will be a share ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. · 2003: Operating loss of 29 million EUR, net loss of 31 million EUR in line with company's forecast · Forecast for 2004: Revenues to quadruple, loss to be cut by half Martinsried - San ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Martinsried - San Diego, January 26, 2004: The German-American biotechnology company MediGene AG (Frankfurt, Prime Standard: MDG) has received marketing authorization for Germany from ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Martinsried - San Diego, January 14, 2004. The German-American biotechnology company MediGene AG (Frankfurt, Prime Standard: MDG) has concluded a partnership with the pharmaceuticals group ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Martinsried - San Diego, December 2, 2003: As the first German biotechnology company, MediGene AG (Frankfurt, Prime Standard: MDG) has received marketing authorization for a drug. The ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Martinsried/San Diego, March 31, 2003: Today the biopharmaceutical company MediGene AG (TecDax: MDG) and the seed capital investment company BioM AG jointly established LARNAX GmbH for the discovery ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Martinsried/San Diego, March 25, 2003. The biopharmaceutical company MediGene AG (TechDax30: MDG) will discontinue the development project of a CVLP tumor vaccine against cervical cancer. The data obtained from a clinical phase 1/2 trial with the ...
Ad hoc-announcement. The sender is solely responsible for the contents of this announcement. Internet: ...
Ad hoc-announcement edited and sent by DGAP. The sender is solely responsible for the contents of this announcement. Internet: ...
